Core Viewpoint - Macquarie's report indicates that Giant Bio (02367) has shown solid performance in the first half of the year, with revenue increasing by 22.5% year-on-year and net profit rising by 20.2% [1] Financial Performance - Revenue increased by 22.5% year-on-year [1] - Net profit rose by 20.2% [1] Future Outlook - Macquarie expects more high-profile KOLs to participate in live streaming during the pre-sale period of Double Eleven [1] - The net profit forecasts for Giant Bio have been raised by 2.7% and 5.8% for the current and next year, respectively, reflecting better-than-expected profits in the first half and gradual recovery in Comfy's sales [1] - The target price has been increased from 76 HKD to 80 HKD, maintaining an outperform rating [1] Marketing Strategy - The company is expected to increase advertising and promotional efforts to conduct a series of marketing activities during Double Eleven to rebuild consumer trust [1] - Investment growth is anticipated to be manageable, with potential offsets from improved operational efficiency and favorable changes in e-commerce platform combinations [1] Channel Stability - Offline channels, including pharmacies and OTC channels, remain stable, indicating no need for additional investment [1] - The developing partnership with Sephora is also highlighted as a point of interest for the market [1]
麦格理：升巨子生物(02367)目标价至80港元 评级“跑赢大市”